Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML

Bing Z Carter, PhD, Po Yee Mak, Vivian Ruvolo, MS, Wenjing Tao, Paul Hughes, Xiaoyue Chen, PK Morrow, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-141399

Published: 2020

Journal Articles

BCL2A1 : A Novel Target in Refractory Acute Myeloid Leukemia with FLT3 -ITD/D835 Dual Mutations

Kotoko Yamatani, MD, Tomohiko Ai, MDPhD, Kaori Saito, Haeun Yang, Vivian Ruvolo, MS, Po Yee Mak, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Hironori Harada, MD PhD, Kazuhiro Katayama, PhD, Takashi Miida, MD PhD, Marina Konopleva, MD PhD, Weiguo Zhang, MD PhD, Bing Z Carter, PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136587

Published: 2020

Journal Articles

High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML

Muharrem Muftuoglu, MD, Po Yee Mak, Vivian Ruvolo, MS, Yuki Nishida, MDPhD, Peter P. Ruvolo, PhD, Bing Z Carter, PhD, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-143371

Published: 2020

Journal Articles

High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Relapsed/Refractory AML By Concomitant Analysis of Cell Surface Antigens, Signaling Pathways and Anti-Apoptotic Proteins

Muharrem Muftuoglu, MD, Zoe Alaniz, BS, Duncan Mak, BSc, MPhil, Angelique J. Lin, MS, Jared K. Burks, PhD, Bing Z Carter, PhD, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-143432

Published: 2020

Journal Articles

Low-Dose Triptolide Promotes MDM2 Inhibitor Nutlin3a to Induce Acute Myeloid Leukemia Cell Death Via p53-Dependent and -Independent Mechanisms

Qinwei Chen, MD PhD, Suqi Deng, MS, Zhijuan Lin, MD PhD, Manman Deng, MD PhD, Lihong Ding, MS, Jie Zha, MD PhD, Yong Zhou, MS, Yuelong Jiang, MS, Bing Z Carter, PhD, Bing Xu, MD PhD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-141315

Published: 2020

Journal Articles

Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML

Bing Z Carter, PhD, Po Yee Mak, Wenjing Tao, Vivian Ruvolo, MS, Xuan Zhang, PhD, Yuki Nishida, MD PhD, Steven M. Kornblau, MD, Paul Hughes, Xiaoyue Chen, PK Morrow, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-141417

Published: 2020

Journal Articles

TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1

Bing Z Carter, PhD, Po Yee Mak, Steven M. Kornblau, MD, Wenjing Tao, Yuki Nishida, MD PhD, Vivian Ruvolo, MS, Justin Cidado, PhD, Lisa Drew, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1271.

https://doi.org/10.1182/blood-2019-124826

Published: 2019

Journal Articles

Single-Cell Mapping of Stress Response and Cell Death Pathways in Acute Myeloid Leukemia Reveals Stressor-Specific Alterations and Distinct Response Patterns

Muharrem Muftuoglu, MD, Vivian Ruvolo, Yuki Nishida, MD PhD, Po Yee Mak, Peter P. Ruvolo, PhD, Bing Z Carter, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 882.

https://doi.org/10.1182/blood-2019-131784

Published: 2019

Journal Articles

Combination of BCL-2 Inhibition and Triptolide Causes Synthetic Lethality in Acute Myeloid Leukemia through Preventing Reciprocal Resistance

Bing Xu, Yuanfei Shi, Long Liu, Bing Z Carter, PhD

Blood (2019) 134 (Supplement_1): 2083.

https://doi.org/10.1182/blood-2019-123722

Published: 2019

Journal Articles

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis

Blood (2019) 134 (Supplement_1): 555.

https://doi.org/10.1182/blood-2019-130046

Published: 2019

Journal Articles

Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML

Bing Z Carter, PhD, Po Yee Mak, Marc Warmoes, Wenjing Tao, Philip Lorenzi, Vivian Ruvolo, MS, Lin Tan, Justin Cidado, PhD, Lisa Drew, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3727.

https://doi.org/10.1182/blood-2019-124453

Published: 2019

Journal Articles

Targeting Misfolded p53 and p53 Aggregation to Overcome Resistance to Apoptosis in Acute Myeloid Leukemia

Michael Andreeff, MD PhD, Jianfang Zeng, MD, Alice Soragni, PhD, Vivian Ruvolo, Bing Z Carter, PhD, Jo Ishizawa, MD PhD, Jared K. Burks, PhD, David Eisenberg, PhD

Blood (2019) 134 (Supplement_1): 3786.

https://doi.org/10.1182/blood-2019-130900

Published: 2019

Journal Articles

TP73 As Novel Determinant of Resistance to BCL-2 Inhibition in Acute Myeloid Leukemia

Yuki Nishida, MD PhD, Jo Ishizawa, MD PhD, Vivian Ruvolo, MS, Feng Wang, PhD, Koichi Takahashi, MD, Po Yee Mak, Bing Z Carter, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1251.

https://doi.org/10.1182/blood-2019-127182

Published: 2019

Journal Articles

Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3 -ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations

Kotoko Yamatani, MD, Tomohiko Ai, MD PhD, Kaori Saito, Haeun Yang, Koya Suzuki, PhD, Atsushi Hori, PhD, Yuko Murakami-Tonami, MD PhD, Weiguo Zhang, MD PhD, Bing Z Carter, PhD, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Katayama Kazuhiro, Hironori Harada, MD PhD, Takashi Miida, MD PhD, Neil P. Shah, MD PhD, Marina Y Konopleva, MD PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD

Blood (2019) 134 (Supplement_1): 1264.

https://doi.org/10.1182/blood-2019-124685

Published: 2019

Journal Articles

Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells

Bing Z Carter, PhD, Wenjing Tao, Po Yee Mak, Qi Zhang, PhD, Xiangmeng Wang, Vinitha Mary Kuruvilla, MSc, Carli Stewart, Vivian Ruvolo, MS, Venkata Lokesh Battula, PhD, Marina Y Konopleva, MD PhD, Sean Caenepeel, Jude Canon, PhD, Paul Hughes, PK Morrow, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1267.

https://doi.org/10.1182/blood-2019-125725

Published: 2019

Journal Articles

A Novel Oral Histone Deacetylase Inhibitor Chidamide Is Highly Effective and Well-Tolerated in Adult Early T-Cell Precursor and Ph-like Acute Lymphoblastic Leukemia

Hongsheng Zhou, MD PhD, Ya Gao, MD, Qiang Wang, Rui Cao, Zhongxin Zhen, Qiuli Li, Dainan Lin, Linlin Zhou, Changxin Yin, Han He, Xiaoli Liu, Bing Z Carter, PhD, Qifa Liu, MD

Blood (2018) 132 (Supplement 1): 4011.

https://doi.org/10.1182/blood-2018-99-113712

Published: 2018

Journal Articles

LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial

Blood (2018) 132 (Supplement 1): 687.

https://doi.org/10.1182/blood-2018-99-119753

Published: 2018

Journal Articles

Targeting Wnt/β-Catenin and BCL-2, Two Critical Survival Factors, Synergistically Induces Apoptosis in AML Via Rac1-Mediated MCL-1 Inhibition

Xiangmeng Wang, Po Yee Mak, Wencai Ma, Xiaoping Su, PhD, Hong Mu, MD PhD, Wenjing Tao, Michael Andreeff, MD PhD, Bing Z Carter, PhD

Blood (2018) 132 (Supplement 1): 1442.

https://doi.org/10.1182/blood-2018-99-118367

Published: 2018

Journal Articles

Mcl-1/CDK9 Targeting By AZD5991/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in Vitro and In Vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions

Bing Z Carter, PhD, Po Yee Mak, Wenjing Tao, Mark Warmoes, Philip L Lorenzi, PhD, Duncan Mak, BSc, MPhil, Vivian Ruvolo, MS, Xiangmeng Wang, Huaxian Ma, MS, Hong Mu, MD PhD, Justin Cidado, PhD, Lisa Drew, PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 768.

https://doi.org/10.1182/blood-2018-99-113491

Published: 2018

Journal Articles

Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis

Naveen Pemmaraju, MD, Bing Z Carter, PhD, Hagop M. Kantarjian, MD, Prithviraj Bose, MD, Tapan Kadia, MD, Elias J. Jabbour, MD, Courtney D. DiNardo, MDMSc, Naval Daver, MD, Zeev Estrov, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Lingsha Zhou, Po Yee Mak, Karina Salinas, RN, Carla Kay Tuttle, RN, Sherry Pierce, BSN, BA, Uday Popat, MD, Srdan Verstovsek, MD PhD

Blood (2017) 130 (Supplement 1): 256.

https://doi.org/10.1182/blood.V130.Suppl_1.256.256

Published: 2017

NARROW

Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML

BCL2A1 : A Novel Target in Refractory Acute Myeloid Leukemia with FLT3 -ITD/D835 Dual Mutations

High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML

High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Relapsed/Refractory AML By Concomitant Analysis of Cell Surface Antigens, Signaling Pathways and Anti-Apoptotic Proteins

Low-Dose Triptolide Promotes MDM2 Inhibitor Nutlin3a to Induce Acute Myeloid Leukemia Cell Death Via p53-Dependent and -Independent Mechanisms

Co-Targeting MCL-1 and BCL-2 Is Highly Synergistic in BH3 Mimetic- and Venetoclax/Hypomethylating Agent-Resistant and TP53 Mutated AML

TP53 Deficient/Mutant AMLs Are Resistant to Individual BH3 Mimetics: High Efficacy of Combined Inhibition of Bcl-2 and Mcl-1

Single-Cell Mapping of Stress Response and Cell Death Pathways in Acute Myeloid Leukemia Reveals Stressor-Specific Alterations and Distinct Response Patterns

Combination of BCL-2 Inhibition and Triptolide Causes Synthetic Lethality in Acute Myeloid Leukemia through Preventing Reciprocal Resistance

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis

Inhibition of Anti-Apoptotic Mcl-1 Exerts Anti-Leukemia Activity through Modulation of Leukemia-Stromal Interactions and Metabolic Functions in AML

Targeting Misfolded p53 and p53 Aggregation to Overcome Resistance to Apoptosis in Acute Myeloid Leukemia

TP73 As Novel Determinant of Resistance to BCL-2 Inhibition in Acute Myeloid Leukemia

Cage Transcriptome Analysis Reveals BCL2A1 Upregulation in FLT3 -ITD/D835 Dual Mutated AML Cells Harboring Complex Co-Mutations

Inhibition of Mcl-1 Enhances the Efficacy of Tyrosine Kinase Inhibition in FLT3 Mutated AML and Synergizes with Venetoclax Targeting AML Stem Cells

A Novel Oral Histone Deacetylase Inhibitor Chidamide Is Highly Effective and Well-Tolerated in Adult Early T-Cell Precursor and Ph-like Acute Lymphoblastic Leukemia

LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial

Targeting Wnt/β-Catenin and BCL-2, Two Critical Survival Factors, Synergistically Induces Apoptosis in AML Via Rac1-Mediated MCL-1 Inhibition

Mcl-1/CDK9 Targeting By AZD5991/AZD4573 Overcomes Intrinsic and Acquired Venetoclax Resistance in Vitro and In Vivo in PDX Model of AML through Modulation of Cell Death and Metabolic Functions

Interim Phase 2 Clinical Trial Results for LCL161, an Oral Smac Mimetic, in Patients with Intermediate or High Risk Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only